Log in

Relevant bibliographies by topics / BCL7 / Journal articles

To see the other types of publications on this topic, follow the link: BCL7.

Journal articles on the topic 'BCL7'

Author: Grafiati

Published: 21 December 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'BCL7.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Dietrich, Nicholas, Kevin Trotter, James M. Ward, and Trevor K. Archer. "BRG1 HSA domain interactions with BCL7 proteins are critical for remodeling and gene expression." Life Science Alliance 6, no. 5 (2023): e202201770. http://dx.doi.org/10.26508/lsa.202201770.

Full text

Abstract:

The SWI/SNF complex remodels chromatin in an ATP-dependent manner through the subunits BRG1 and BRM. Chromatin remodeling alters nucleosome structure to change gene expression; however, aberrant remodeling can result in cancer. We identified BCL7 proteins as critical SWI/SNF members that drive BRG1-dependent gene expression changes. BCL7s have been implicated in B-cell lymphoma, but characterization of their functional role within the SWI/SNF complex has been limited. This study implicates their function alongside BRG1 to drive large-scale changes in gene expression. Mechanistically, the BCL7

APA, Harvard, Vancouver, ISO, and other styles

2

Jadayel, Dalal M., Lucy R. Osborne, Lionel J. A. Coignet, et al. "The BCL7 gene family: deletion of BCL7B in Williams syndrome." Gene 224, no. 1-2 (1998): 35–44. http://dx.doi.org/10.1016/s0378-1119(98)00514-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

McBride, Amanda, Clare M. Adams, Ramkrishna Mitra, and Christine M. Eischen. "Bclw Overexpression Predicts Aggressive Disease in B-Cell Lymphomas." Blood 136, Supplement 1 (2020): 29. http://dx.doi.org/10.1182/blood-2020-142545.

Full text

Abstract:

B-cell lymphomas encompass a phenotypically and genetically heterogenous subgroup within hematologic malignancies. Despite this heterogeneity, the ability to evade apoptosis is a unifying feature across B-cell lymphomas, and alterations within the Bcl-2 family of apoptosis regulatory proteins is a key mechanism for this evasion. While overexpression of the anti-apoptotic Bcl-2 family member BCL2 has been widely described in multiple B-cell lymphomas, altered expression of other anti-apoptotic proteins within this family, including BCLX, MCL1, A1 and, in particular, BCLW has been under-investig

APA, Harvard, Vancouver, ISO, and other styles

4

Kahraman, Dudu Solakoglu, Gulden Diniz, Cengiz Ceylan, et al. "Prognostic impact of BCL2, BCL6 and MYC status in de novo diffuse large B-cell lymphoma: a regional study of 43 patients." International Journal of Research in Medical Sciences 7, no. 5 (2019): 1720. http://dx.doi.org/10.18203/2320-6012.ijrms20191665.

Full text

Abstract:

Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with marked biologic heterogeneity. We aimed to evaluate the status of MYC, BCL2, BCL6 in patients with DLBCL.Methods: Herein, we have investigated the prognostic relevance of MYC, BCL2 and BCL6 from 43 de novo DLBCL patients.Results: In this study, protein overexpression of BCL2 and BCL6 was encountered in 46.5% (n=20) and 27.9% (n=12) of the tumors, respectively. Rearrangements in MYC, BCL6, and BCL2 were detected in 9.3% (n=4), 25.6% (n=11), and 4.7% (n=2) of the cases, respectively. Any statistically si

APA, Harvard, Vancouver, ISO, and other styles

5

Sun, Guoxian, and Lya Montella. "Oncogene Amplification as an Incidental Finding in FISH Testing for Gene Rearrangements in Lymphoid Hematopoietic Neoplasms." Blood 118, no. 21 (2011): 2505. http://dx.doi.org/10.1182/blood.v118.21.2505.2505.

Full text

Abstract:

Abstract Abstract 2505 Oncogene amplification resulting in overexpression, although common in solid tumors, is rare in hematopoietic neoplasms. This is particularly true in lymphoid neoplasms compared to AML where MYC, MLL or RUNX1 (AML1) amplification has been mostly seen, and to CML where BCR/ABL fusion gene amplification has been also reported. Typically, lymphoid neoplasms are tested at diagnosis by FISH for specific reciprocal chromosome translocations that lead to overexpression of deregulated oncogenes such as BCL1, BCL2, BCL6 and MYC in B-cell lymphoma and myeloma or BCR/ABL gene fusio

APA, Harvard, Vancouver, ISO, and other styles

6

González de Villambrosia, Sonia, Mercedes Colorado, Andres Insunza, et al. "B Cell Lymphoma Unclassifiable, with Features Intermediate Between Diffuse Large B Cell Lymphoma and Burkitt Lymphoma and Diffuse Large B Cell Lymphoma NOS with Doble/Triple Translocations: Immunophenotypic Analysis." Blood 126, no. 23 (2015): 5037. http://dx.doi.org/10.1182/blood.v126.23.5037.5037.

Full text

Abstract:

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is a clinically and molecularly heterogeneous disease. We can identify two subgroups with aggressive clinical course and higher risk of treatment failure after standard therapy: B cell lymphoma unclassifiable (BCLU) with features intermediate between DLBCL and Burkitt lymphoma (BL) and B-cell lymphomas with double/triple translocation (DHL/THL). Previous reports suggest that these types of lymphomas may show a common immunophenotype, providing another tool in the challenge of their diagnosis. Objetives: To analyze the immnunophenotype

APA, Harvard, Vancouver, ISO, and other styles

7

Leski, Tomasz A., Clayton C. Caswell, Marcin Pawlowski, et al. "Identification and Classification of bcl Genes and Proteins of Bacillus cereus Group Organisms and Their Application in Bacillus anthracis Detection and Fingerprinting." Applied and Environmental Microbiology 75, no. 22 (2009): 7163–72. http://dx.doi.org/10.1128/aem.01069-09.

Full text

Abstract:

ABSTRACT The Bacillus cereus group includes three closely related species, B. anthracis, B. cereus, and B. thuringiensis, which form a highly homogeneous subdivision of the genus Bacillus. One of these species, B. anthracis, has been identified as one of the most probable bacterial biowarfare agents. Here, we evaluate the sequence and length polymorphisms of the Bacillus collagen-like protein bcl genes as a basis for B. anthracis detection and fingerprinting. Five genes, designated bclA to bclE, are present in B. anthracis strains. Examination of bclABCDE sequences identified polymorphisms in

APA, Harvard, Vancouver, ISO, and other styles

8

Dupont, Thibault, Zhenghong Dong, ShaoNing Yang, Ari Melnick, and Leandro Cerchietti. "Combinatorial Targeting of BCL6 and Anti-Apoptotic Proteins in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)." Blood 120, no. 21 (2012): 64. http://dx.doi.org/10.1182/blood.v120.21.64.64.

Full text

Abstract:

Abstract Abstract 64 BCL6 represents a survival factor in DLBCL and FL since specific BCL6 inhibitors (i.e: the peptidomimetic RI-BPI and the small molecule 79-6) kill DLBCL and transformed FL (tFL) cell lines. Our group showed that BCL2 and other anti-apoptotic genes are transcriptionally repressed by BCL6 and could be reactivated upon treatment with RI-BPI or 79-6. We also showed that BCL6 and BCL2 control distinct and non-overlapping survival pathways in these lymphomas. This suggests that blocking the function of anti-apoptotic proteins might overcome any resistance that these proteins mig

APA, Harvard, Vancouver, ISO, and other styles

9

Pophali, Priyanka, Lisa M. Marinelli, Rhett P. Ketterling, et al. "High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease?" Blood 132, Supplement 1 (2018): 1693. http://dx.doi.org/10.1182/blood-2018-99-115484.

Full text

Abstract:

Abstract MYC amplification (amp) is a marker of poor prognosis in many non-hematologic malignancies. While MYC translocations in B cell lymphoma (BCL) have been extensively studied, little is known about the significance of MYC amp. Recent studies describe increased MYC copy numbers (3-10 copies/cell) to be associated with more aggressive BCL. The WHO 2017 does not include MYC amp in the definition of high-grade BCL (HGBCL) with MYC and BCL2 and/or BCL6 rearrangement ("double-hit lymphoma", DHL). However, it also states that high-level MYC amp occurring together with a MYC rearrangement, and c

APA, Harvard, Vancouver, ISO, and other styles

10

Pedersen, Mette Ølgod, Anne Ortved Gang, Tim Svenstrup Poulsen, et al. "Concurrent BCL2 and MYC Translocations In a Prospective Cohort of Diffuse Large B-Cell Lymphomas." Blood 116, no. 21 (2010): 319. http://dx.doi.org/10.1182/blood.v116.21.319.319.

Full text

Abstract:

Abstract Abstract 319 Background: Concurrent chromosomal translocations involving the BCL2 and MYC protooncogenes, so-called double-hit, is found both in diffuse large B-cell lymphoma (DLBCL) and in a newly defined B-cell lymphoma category with features overlapping between DLBCL and Burkitt lymphoma (BCLU, 2008 WHO classification). Few studies have been published on series of double-hit B-cell lymphomas, and to our knowledge only retrospective series, reporting an average frequency of around 5%. Therefore some authors suspected that the frequency of double-hit translocations was underestimated

APA, Harvard, Vancouver, ISO, and other styles

11

Shivam, Saloni, Mansour El-Matbouli, and Gokhlesh Kumar. "Kinetics of Parasite-Specific Antibody and B-Cell-Associated Gene Expression in Brown Trout, Salmo trutta during Proliferative Kidney Disease." Biology 10, no. 12 (2021): 1244. http://dx.doi.org/10.3390/biology10121244.

Full text

Abstract:

Tetracapsuloides bryosalmonae, a myxozoan endoparasite often causes chronic infection in brown trout. Antiparasite immunity mediated by antibodies and B cells is known as an important determinant of host survival and parasite proliferation during chronic infections. Accordingly, studying their time course during proliferative kidney disease (PKD) might be helpful in improving our understanding of its chronic nature. Therefore, we conducted this study to examine parasite specific serum antibody and B-cell-mediated response in laboratory-infected brown trout at different time points. Brown trout

APA, Harvard, Vancouver, ISO, and other styles

12

Piovan, Erich, Masumichi Saito, Katia Basso, et al. "Direct Transcriptional Repression of BCL2 by BCL6 in Germinal Centre B Cells and Its Disruption in B Cell Lymphomas with BCL2 Locus Alterations." Blood 112, no. 11 (2008): 296. http://dx.doi.org/10.1182/blood.v112.11.296.296.

Full text

Abstract:

Abstract The human proto-oncogene BCL6 encodes a BTB/POZ-zinc finger transcriptional repressor that is required for germinal centre (GC) development and is expressed in the majority of normal GC B cells and in the majority of B cell lymphoma (B-NHL), including follicular lymphoma (FL) and a subset of diffuse large B cell lymphomas (DLBCLs). Deregulation of BCL6, by chromosomal translocation or somatic hypermutation, is implicated in the pathogenesis of B-NHL. The precise function of BCL6 in GC development and lymphomagenesis is still unclear also due to the very few direct BCL6 target genes th

APA, Harvard, Vancouver, ISO, and other styles

13

Palathingal Bava, E., W. liu, Y. Shen, et al. "Composite Lymphoma Comprising of BCL2 Rearrangement Negative, CD23 Positive Follicle Center Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Case Report." American Journal of Clinical Pathology 162, Supplement_1 (2024): S75—S76. http://dx.doi.org/10.1093/ajcp/aqae129.167.

Full text

Abstract:

Abstract Introduction/Objective BCL2 rearrangement negative, CD23-positive follicle center cell lymphoma (BCL2 neg CD23 pos FCL) is a rare, recently described provisional entity in International Consensus Classification (2022). It has a predominantly diffuse growth pattern and often involves inguinal region. The molecular profile includes a high frequency of STAT6 and CREBBP co-mutation as well as 1q gain and a recurrent 1p36 loss/TNFRS14 abnormalities. We describe a composite tumor comprising of a rare entity BCL2 neg CD23 pos FCL and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (C

APA, Harvard, Vancouver, ISO, and other styles

14

Botto, Barbara, Domenico Novero, Annalisa Chiappella, et al. "The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP." Blood 124, no. 21 (2014): 2964. http://dx.doi.org/10.1182/blood.v124.21.2964.2964.

Full text

Abstract:

Abstract Introduction : MYC, BCL2 and BCL6 overexpression, assessed by IHC, with the latter conferring a better prognosis, have been reported to be a prognostic factor in DLBCL, but data are not consistent and sometimes contradictory. The aim of the present study was to assess the prognostic impact of overexpression of MYC, BCL2, and BCL6 in a retrospective cohort of de-novo DLBCL, selected for an high proliferation index (MIB1 ≥70%), treated consecutively with R-CHOP regimen. Methods: Patients with de-novo DLBCL diagnosed between January 2010 and December 2013 were included into the study. In

APA, Harvard, Vancouver, ISO, and other styles

15

Navarro, Jose-Tomas, Maria Joao Baptista, Alejandra Martinez-Trillos, et al. "Lymphomas With MYC-Translocation Other Than Burkitt’s Have An Aggressive Presentation and Poor Response To Immunochemotherapy: Study Of 34 Cases." Blood 122, no. 21 (2013): 5083. http://dx.doi.org/10.1182/blood.v122.21.5083.5083.

Full text

Abstract:

Abstract Introduction MYC translocations involving chromosome 8q24 can occur in a wide variety of B-cell lymphomas other than Burkitt’s lymphoma (BL), especially diffuse large B-cell lymphoma (DLBCL) and B-cell lymphoma unclassifiable with intermediate features between DLBCL and BL (BCLU). These lymphomas can harbor additional translocations of BCL2 and/or BCL6, that have been referred to as double and triple-hit lymphomas. MYC positive lymphomas other than BL are not well characterized and the standard treatment has to be established. Aim The objective was to study the clinic-biological chara

APA, Harvard, Vancouver, ISO, and other styles

16

Yang, Ge, Pin Wan, Qi Xiang, et al. "E3 Ubiquitin Ligase ASB17 Promotes Apoptosis by Ubiquitylating and Degrading BCLW and MCL1." Biology 10, no. 3 (2021): 234. http://dx.doi.org/10.3390/biology10030234.

Full text

Abstract:

Apoptosis is a very important process of cell death controlled by multiple genes during which cells undergo certain events before dying. Apoptosis helps to clean the unnecessary cells and has critical physiological significance. Altered apoptosis results in a disorder of cell death and is associated with many diseases such as neurodegenerative diseases and cancers. Here, we reported that the ankyrin repeat and SOCS box protein 17 (ASB17) was mainly expressed in the testis and promoted apoptosis both in vivo and in vitro. Analyzing ASB17-deficient mice generated by using the CRISPR/Cas9 system,

APA, Harvard, Vancouver, ISO, and other styles

17

Hildebrand, Johannes Adrian, Sarah Haebe, Verena Passerini, et al. "Lysosomal Membrane Permeabilization Sensitizes Ctss-Hyperactive Tumors to BCL2-Targeting Therapies." Blood 142, Supplement 1 (2023): 4358. http://dx.doi.org/10.1182/blood-2023-174384.

Full text

Abstract:

Hyperactivity of the cysteine protease cathepsin S (CTSS) -either through Y132 mutations or amplification/overexpression- is a recurrent alteration in follicular lymphoma (FL) and promotes tumor growth by inducing a supportive immune microenvironment (Bararia et al, 2020). Of note, patients with CTSS-hyperactive FL had better outcomes with standard therapies, suggesting that CTSS-hyperactivity can sensitize tumors to treatment. CTSS hyperactivity has also been reported in other B cell lymphomas (BCLs) (Dheilly et al, 2020) and solid cancers (Olson & Joyce, 2015). CTSS is mainly localized i

APA, Harvard, Vancouver, ISO, and other styles

18

Swerdlow, Steven H. "Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC." Hematology 2014, no. 1 (2014): 90–99. http://dx.doi.org/10.1182/asheducation-2014.1.90.

Full text

Abstract:

Abstract Identification of large B-cell lymphomas that are “extra-aggressive” and may require therapy other than that used for diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), is of great interest. Large B-cell lymphomas with MYC plus BCL2 and/or BCL6 rearrangements, so-called ‘double hit’ (DHL) or ‘triple hit’ (THL) lymphomas, are one such group of cases often recognized using cytogenetic FISH studies. Whether features such as morphologic classification, BCL2 expression, or type of MYC translocation partner may mitigate the very adverse prognosis of DHL/THL is controversia

APA, Harvard, Vancouver, ISO, and other styles

19

Patel, Priyank P., Pallawi Torka, Vishala T. Neppalli, et al. "Intense Cytarabine-Based Chemo-Immunotherapy, Central Nervous System (CNS) Prophylaxis and Early High-Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS) in First Remission Are Associated with an Improved Clinical Outcome in Double-Hit (DHL)/Triple-Hit (THL) Diffuse Large B-Cell Lymphoma (DLBCL)." Blood 124, no. 21 (2014): 3031. http://dx.doi.org/10.1182/blood.v124.21.3031.3031.

Full text

Abstract:

Abstract Based on molecular studies, DLBCL is now further divided in three subtypes with distinct pathogenesis and clinical outcomes. Fluorescence in situ hybridization (FISH) studies identified a subgroup of DLBCL with a poor clinical outcome harboring concurrent gene rearrangements of the MYC, BCL2 and/or BCL6 proto-oncogenes leading to the over-expression of c-Myc, Bcl-2 and Bcl-6, inferior response rates to rituximab-based chemotherapy, and a shorter progression-free survival (PFS)/overall survival (OS). This group of patients is now categorized as double-hit (DHL) or triple-hit (THL) DLBC

APA, Harvard, Vancouver, ISO, and other styles

20

Walia, Jasmit, Timothy Daly, Ali Tahir, Melissa Wilson, and Kunal Bhagatwala. "A case of triple hit lymphoma and rapid deterioration." Journal of Case Reports and Images in Oncology 9, no. 1 (2023): 8–11. http://dx.doi.org/10.5348/100118z10jw2023cr.

Full text

Abstract:

Triple hit lymphomas (THL) comprise a rare, heterogenous group of lymphomas and like many B-cell lymphomas, chromosomal translocations are biologic and diagnostic hallmarks of disease. Traditionally referred to as a subset of double hit lymphomas (DHL) in literature, THLs characteristically involve chromosomal rearrangements of c-MYC, BCL-2, and BCL-6 oncogenes. Many case series of high-grade B-cell lymphoma, especially MYC/BCL2 double hit lymphoma, have been described in the literature, but relatively few cases of triple hit lymphoma have been reported. Additionally, without chemotherapy, tri

APA, Harvard, Vancouver, ISO, and other styles

21

Carey, Christopher Daniel, Daniel Gusenleitner, Zhang Xuan, et al. "Resolving the Biological Heterogeneity of B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between DLBCL and BL (BCL-U) Using Quantitative Profiles of Oncogenic Signaling Networks." Blood 126, no. 23 (2015): 3903. http://dx.doi.org/10.1182/blood.v126.23.3903.3903.

Full text

Abstract:

Abstract BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) have characteristic cellular, phenotypic, and genetic characteristics that reflect their distinctive biology. These distinctions are attributable, in part, to differential activity of defined oncogenic signaling pathways, including TCF3/ID3, NFkB, MYC, and BCL2 (Carey et al, JMD, 2015). B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL (BCL-U) encompasses a group of tumors with ambiguous features and likely heterogeneous biology. We used targeted gene expression profiling and a m

APA, Harvard, Vancouver, ISO, and other styles

22

Trajkova, Sanja, Svetlana Krstevska-Balkanov, Gordana Petrusevska, et al. "Prognostic impact of immunophenotyping of diffuse large B-cell lymphoma - a single-centre experience." Macedonian Pharmaceutical Bulletin 67, no. 1 (2021): 43–54. http://dx.doi.org/10.33320/10.33320/maced.pharm.bull.2021.67.01.005.

Full text

Abstract:

The concept generated by biological expression profile divided patients with diffuse large B-cell lymphoma (DLBCL) into two subtypes. This concept has been presented in the recent editions of WHO classification and became a prognostic tool. Aim of the study was introduction of new three-marker model for immunohistochemical and prognostic subclasification of patients with DLBCL. Our retrospective study enrolled 200 adult patients with DLBCL diagnosed and treated in the period between January 2013 to January 2021. They were all treated with chemoimmunotherapy with R+/-CHOP regimen and the median

APA, Harvard, Vancouver, ISO, and other styles

23

Amallraja, Anu, Gunes Gundem, Dylan Domenico, et al. "Genomic Characterization and Classification of BCL6 Rearranged Follicular Lymphomas." Blood 144, Supplement 1 (2024): 1589. https://doi.org/10.1182/blood-2024-203770.

Full text

Abstract:

Introduction Follicular lymphoma (FL) is the most common type of indolent non-Hodgkin's lymphoma with BCL6 rearrangements (BCL6-R) observed in 5-15% of cases. BCL6-R FL frequently exhibit concurrent canonical BCL2 rearrangements (BCL2-R). However, a subset presents with BCL6-R exclusively and shares biological features with the recently described genomic subgroup of diffuse large B-cell lymphoma, BN2, characterized by BCL6-R and a mutational profile suggestive of marginal zone lymphoma (MZL) (Schmitz 2018). In this study, we analyzed 14 BCL6-R FL samples to study the mechanisms generating the

APA, Harvard, Vancouver, ISO, and other styles

24

Haralambieva, Eugenia, Evert-jan Boerma, Gustaaf van Imhoff, et al. "The Grey Zone between Burkitt and Diffuse Large B Cell Lymphomas: Impact of Chromosomal Breakponts at Myc and Other Loci." Blood 104, no. 11 (2004): 2275. http://dx.doi.org/10.1182/blood.v104.11.2275.2275.

Full text

Abstract:

Abstract A prompt distinction of Burkitt lymphoma (BL) versus diffuse large B cell lymphoma (DLBCL) has important clinical implications. We analyzed 74 adult grey zone lymphomas (BL/DLBCL) and 10 reference pediatric BL using immunohistochemistry for Ki-67, CD10, bcl2 and bcl6, and Fluorescence In Situ Hybridization (FISH) for MYC, BCL2 and BCL6 breakpoints. Four hematopathologists reached a final (consensus) diagnosis independently in 80% of the reference BL, 24% of the test BL and 69% of the DLBCL. A MYC breakpoint was detected in all reference BL, 95% of the test BL and 35% of the DLBCL. BCL

APA, Harvard, Vancouver, ISO, and other styles

25

Ci, Weimin, Jose M. Polo, Leandro Cerchietti, et al. "The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL." Blood 113, no. 22 (2009): 5536–48. http://dx.doi.org/10.1182/blood-2008-12-193037.

Full text

Abstract:

The BCL6 transcriptional repressor is required for development of germinal center (GC) B cells and when expressed constitutively causes diffuse large B-cell lymphomas (DLBCLs). We examined genome-wide BCL6 promoter binding in GC B cells versus DLBCLs to better understand its function in these settings. BCL6 bound to both distinct and common sets of functionally related gene in normal GC cells versus DLBCL cells. Certain BCL6 target genes were preferentially repressed in GC B cells, but not DLBCL cells. Several such genes have prominent oncogenic functions, such as BCL2, MYC, BMI1, EIF4E, JUNB,

APA, Harvard, Vancouver, ISO, and other styles

26

Arun Kumar, Sumukh, Rahul Mishra, Sarat Chandra Malempati, and Poorva Bindal. "Primary cardiac large B cell lymphoma." BMJ Case Reports 16, no. 12 (2023): e256167. http://dx.doi.org/10.1136/bcr-2023-256167.

Full text

Abstract:

A female patient in her mid-60s presented with progressive shortness of breath, pleuritic chest pain and bilateral leg swelling for 1 week. Initial diagnostic workup revealed pericardial effusion, and a localised pericardial tubular mass on CT chest. Pericardial fluid analysis showed elevated white cells, with predominance of medium-large sized atypical lymphoid cells. Atypical lymphocytes stained positive for CD79a, CD10, PAX-5, BCL-2 and BCL6. Fluorescence in situ hybridisation testing demonstrated MYC and BCL6 rearrangements without BCL2 gene rearrangement. The overall morphological, immuno

APA, Harvard, Vancouver, ISO, and other styles

27

Kawakami, Keiki, Setsuko Miyanishi, Takashi Sonoki, et al. "Case of B-Cell Lymphoma with Rearrangement of the BCL1, BCL2, BCL6, and c-MYC Genes." International Journal of Hematology 79, no. 5 (2004): 474–79. http://dx.doi.org/10.1532/ijh97.03105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Tsai, Cheng-Chih, Yung-Cheng Su, Oluwaseun Adebayo Bamodu, et al. "High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan." Cancers 13, no. 7 (2021): 1620. http://dx.doi.org/10.3390/cancers13071620.

Full text

Abstract:

This study investigated the epidemiological and clinical peculiarities of BCL2 and BCL6 rearrangement in patients with high grade B-cell lymphoma (HGBL) from Taiwan, compared with data from Western countries. Two hundred and eighty-two DLBCL cases from Taipei Medical University-affiliated hospitals (n = 179) and Tri-Service General Hospital (n = 103) were enrolled for this study. From the 282, 47 (16.7%) had MYC translocation; 24 of these harbored concurrent BCL2 and/or BCL6 translocation (double-hit, DH or triple-hit, TH). Twelve DH-HGBL cases had simultaneous MYC and BCL6 translocations, 8 h

APA, Harvard, Vancouver, ISO, and other styles

29

Biehl, Holger, Jeremy C. Creasey, David M. Smith, et al. "Vacuum UV fluorescence excitation spectroscopy of BCl3. Electronic spectroscopy of BCl2, BCl2 + and BCl3 +." Journal of the Chemical Society, Faraday Transactions 91, no. 18 (1995): 3073. http://dx.doi.org/10.1039/ft9959103073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Dierlamm, J., S. Pittaluga, I. Wlodarska, et al. "Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features [see comments]." Blood 87, no. 1 (1996): 299–307. http://dx.doi.org/10.1182/blood.v87.1.299.299.

Full text

Abstract:

Abstract Clinical, histologic, cytogenetic, and molecular genetic data of 31 patients with extranodal, nodal, and splenic marginal zone B-cell lymphoma (MZBCL) are presented. Despite these variable clinical manifestations, a similar spectrum of morphologic features as well as distinctive immunophenotypic findings were noted. In all cases, a monotypic B-cell proliferation consistently negative for CD5, CD10, and CD23 was found expanding the marginal zone of the B follicle with and without colonization of the follicle centers. Clonal chromosomal abnormalities were detected in 23 of the 31 patien

APA, Harvard, Vancouver, ISO, and other styles

31

Dierlamm, J., S. Pittaluga, I. Wlodarska, et al. "Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features [see comments]." Blood 87, no. 1 (1996): 299–307. http://dx.doi.org/10.1182/blood.v87.1.299.bloodjournal871299.

Full text

Abstract:

Clinical, histologic, cytogenetic, and molecular genetic data of 31 patients with extranodal, nodal, and splenic marginal zone B-cell lymphoma (MZBCL) are presented. Despite these variable clinical manifestations, a similar spectrum of morphologic features as well as distinctive immunophenotypic findings were noted. In all cases, a monotypic B-cell proliferation consistently negative for CD5, CD10, and CD23 was found expanding the marginal zone of the B follicle with and without colonization of the follicle centers. Clonal chromosomal abnormalities were detected in 23 of the 31 patients. Recur

APA, Harvard, Vancouver, ISO, and other styles

32

Horn, Heike, Marita Ziepert, Thomas F. E. Barth, et al. "The Prognostic Impact Of Gene Rearrangements and Protein Expression Of MYC, BCL2 and BCL6 In Young High-Risk Patients With DLBCL." Blood 122, no. 21 (2013): 4262. http://dx.doi.org/10.1182/blood.v122.21.4262.4262.

Full text

Abstract:

Abstract Purpose A number of retrospective analyses have looked into the prognostic implication of MYC, BCL2 and BCL6 rearrangements and protein expression for MYC, BCL2 and BCL6 in patients with diffuse large B-cell lymphoma (DLBCL). Many of these studies suffer from small patient cohorts and differing or unknown treatment strategies (with or without Rituximab) administered to patients under study. Furthermore, the median age of these patients was relatively high. We for the first time report on the prognostic consequences of MYC, BCL2 and BCL6 alterations in younger (18-60 years) high-risk p

APA, Harvard, Vancouver, ISO, and other styles

33

Ma, Zhiping, Jing Niu, Yanzhen Cao, et al. "Clinical significance of ‘double-hit’ and ‘double-expression’ lymphomas." Journal of Clinical Pathology 73, no. 3 (2019): 126–38. http://dx.doi.org/10.1136/jclinpath-2019-206199.

Full text

Abstract:

Background‘Double-hit’ lymphoma (DHL) and ‘double-expression’ lymphoma (DEL) involving gene rearrangement and protein expression of MYC and BCL2/BCL6 have recently become the most commonly used terms to describe the poor prognostic types of diffuse large B-cell lymphoma (DLBCL). However, the clinical and pathological spectra of these rare entities have not been well defined. The aim of this study was to determine the frequency of DHL and DEL in DLBCL and their prognostic impacts in the era of cyclophosphamide, doxorubicin, vincristine and prednisone plus rituximab therapy.MethodsThe data and t

APA, Harvard, Vancouver, ISO, and other styles

34

Worrillow, Lisa J., Rob Newton, and Andrew S. Jack. "The Pattern of BCL6 Intron 1 Mutations in Healthy Individuals with BCL2;IgH Is Similar to That Seen in Lymphomas." Blood 112, no. 11 (2008): 3800. http://dx.doi.org/10.1182/blood.v112.11.3800.3800.

Full text

Abstract:

Abstract Mutational clustering in intron 1 of BCL6, and BCL2;IgH translocation are commonly found in peripheral lymphocytes from healthy individuals. These abnormalities, most likely the consequence of mistargeted rearrangement and somatic hypermutation of the immunoglobulin locus, are also associated with lymphoma. However, the relevance of these findings to disease pathogenesis remains unclear. Given that deregulated BCL2 expression is likely to promote cell survival, we hypothesized that the frequency of BCL6 intron 1 mutations would increase in germinal centre B-cells carrying BCL2;IgH. We

APA, Harvard, Vancouver, ISO, and other styles

35

Vallespi, Teresa, Margarita Ortega, Anny Jaramillo, et al. "T(8;22)(q24;q11) In a Context of Complex Karyotype In Two Patients with B-Cell Lymphoma with Features Intermediate Between Burkitt Lymphoma and Diffuse Large B Cell Lymphoma B (LB/LDCGB)." Blood 116, no. 21 (2010): 5093. http://dx.doi.org/10.1182/blood.v116.21.5093.5093.

Full text

Abstract:

Abstract Abstract 5093 Background: In some cases, it is difficult to distinguish between the diagnosis of Burkitt lymphoma (LB) and Diffuse Large Cell Lymphoma B (DLCL-B) with MYC gene rearrangement. The WHO classification distinguishes three clinical entities: LB, LB/DLCL-B, DLCL-B on the basis of morphology, immunophenotype and genetic characteristics of malignant cells. The MYC gene is often rearranged with the gene that encodes the heavy chains of immunoglobulins (IgG 14q32) and, less frequently, with the gene that encodes the light chains kappa (2p12) or lambda (22q11). Objective: Describ

APA, Harvard, Vancouver, ISO, and other styles

36

Kramer, M. H. H., J. Hermans, E. Wijburg, et al. "Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma." Blood 92, no. 9 (1998): 3152–62. http://dx.doi.org/10.1182/blood.v92.9.3152.

Full text

Abstract:

Abstract Diffuse large B-cell lymphoma (DLCL) is characterized by a marked degree of morphologic and clinical heterogeneity. We studied 156 patients with de novo DLCL for rearrangements of the BCL2, BCL6, and MYC oncogenes by Southern blot analysis and BCL2 protein expression. We related these data to the primary site of presentation, disease stage, and other clinical risk factors. Structural alterations of BCL2, BCL6, and MYC were detected in 25 of 156, 36 of 116, and 10 of 151 patients, respectively. Three cases showed a combination of BCL2 and BCL6 rearrangements, and two cases had a combin

APA, Harvard, Vancouver, ISO, and other styles

37

Kramer, M. H. H., J. Hermans, E. Wijburg, et al. "Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma." Blood 92, no. 9 (1998): 3152–62. http://dx.doi.org/10.1182/blood.v92.9.3152.421a07_3152_3162.

Full text

Abstract:

Diffuse large B-cell lymphoma (DLCL) is characterized by a marked degree of morphologic and clinical heterogeneity. We studied 156 patients with de novo DLCL for rearrangements of the BCL2, BCL6, and MYC oncogenes by Southern blot analysis and BCL2 protein expression. We related these data to the primary site of presentation, disease stage, and other clinical risk factors. Structural alterations of BCL2, BCL6, and MYC were detected in 25 of 156, 36 of 116, and 10 of 151 patients, respectively. Three cases showed a combination of BCL2 and BCL6 rearrangements, and two cases had a combination of

APA, Harvard, Vancouver, ISO, and other styles

38

Abramson, Jeremy S., Jeffrey A. Barnes, Yang Feng, et al. "Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy." Blood 120, no. 21 (2012): 1619. http://dx.doi.org/10.1182/blood.v120.21.1619.1619.

Full text

Abstract:

Abstract Abstract 1619 Introduction: Double-hit lymphomas (DHL) harboring rearrangements or additional copies of MYC and BCL2 or less commonly BCL6 have been associated with a poor prognosis, but data remains limited. We conducted a retrospective analysis of DHLs to evaluate for factors associated with an improved prognosis. Methods: We identified DHL cases diagnosed 2004–2011. Cases were included if they had rearrangements or extra copies of MYC as well as BCL2 or BCL6, or both. Overall survival (OS) was defined as the time from biopsy to death. Progression-free survival (PFS) was defined as

APA, Harvard, Vancouver, ISO, and other styles

39

Sakruti, Susmita, Nabila Bennani, Swapna Thota, et al. "Diffuse Large B Cell Lymphoma: Role Of MYC, BCL2, BCL6 Protein Expressions and Translocations." Blood 122, no. 21 (2013): 5055. http://dx.doi.org/10.1182/blood.v122.21.5055.5055.

Full text

Abstract:

Abstract Introduction Diffuse large B cell lymphoma (DLBCL) accounts for approximately 30% of the non-Hodgkin’s lymphomas. However, DLBCL has heterogeneous clinical, histological, and molecular features. It has been identified that the clinical features and the treatment response vary with genetic and molecular features that affect disease aggressiveness. Gene rearrangements and more recently protein expressions involving MYC, BCL2 or BCL6 have been shown to have major prognostic implications. Lymphomas with recurrent chromosomal breakpoints activating multiple oncogenes, (one being MYC), are

APA, Harvard, Vancouver, ISO, and other styles

40

Parkhi, Mayur, Debajyoti Chatterjee, Bishan Dass Radotra, Amanjit Bal, Budhi Singh Yadav, and Manjul Tripathi. "Double-hit and double-expressor primary central nervous system lymphoma: Experience from North India of an infrequent but aggressive variant." Surgical Neurology International 14 (May 12, 2023): 172. http://dx.doi.org/10.25259/sni_307_2023.

Full text

Abstract:

Background: High-grade non-Hodgkin B-cell lymphoma is an aggressive mature B-cell lymphoma that depicts poor treatment response and worse prognosis. The presence of MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements qualifies for triple-hit and double-hit lymphomas (THL/DHL), respectively. We attempted to explore the incidence, distribution, and clinical characteristics of the primary high-grade B-cell lymphoma of the central nervous system (CNS) in our cohort from North India. Methods: All the histologically confirmed cases of primary CNS diffuse large B-cell lymp

APA, Harvard, Vancouver, ISO, and other styles

41

Rossi, Davide, Valeria Spina, Clara Deambrogi, et al. "TP53 Mutations, the Most Frequent Genetic Lesion in Richter Syndrome, Represent An Independent Predictor of Survival Post Transformation." Blood 114, no. 22 (2009): 670. http://dx.doi.org/10.1182/blood.v114.22.670.670.

Full text

Abstract:

Abstract Abstract 670 Richter syndrome (RS) represents the transformation of chronic lymphocytic leukemia (CLL) to aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). Knowledge of the genetic lesions associated with RS is scant and represents the aim of this study. The study was based on 47 RS cases (all DLBCL). In 32 cases, paired CLL/RS samples were available (28 clonally related and 4 clonally unrelated). In 15 cases, the sole RS sample was analysed. According to CD10/BCL6/MUM1 immunohistochemistry expression pattern, 43/47 (91.5%) RS were classified as non-germinal ce

APA, Harvard, Vancouver, ISO, and other styles

42

Meriranta, Leo, Annika Pasanen, Marja-Liisa Karjalainen-Lindsberg, Sandeep Dave, and Sirpa Leppa. "Clinical and Biological Features behind Hallmark Aberrations in Diffuse Large B-Cell Lymphoma." Blood 132, Supplement 1 (2018): 2976. http://dx.doi.org/10.1182/blood-2018-99-117958.

Full text

Abstract:

Abstract Introduction. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy with a diverse genomic appearance. To date, the coding genomes of almost 2000 DLBCLs have been recognized, and the translation of this genetic information into clinical practice is awaited. Here, we have investigated translocations and protein expression of the hallmark DLBCL genes BCL2, BCL6 and MYC in a well-characterized sample series. The findings are correlated with gene expression, copy number alterations (CNAs) and exome-wide mutational annotations, and molecular data associated with clin

APA, Harvard, Vancouver, ISO, and other styles

43

Pajor, László, József Kun, Róbert Herczeg, et al. "A diffúz nagy B-sejtes limfóma fenotipikus, citogenetikai és expressziós profil heterogenitása – Magyarországi multicentrikus tanulmány." Hematológia–Transzfuziológia 55, no. 4 (2023): 154–63. http://dx.doi.org/10.1556/2068.2023.00157.

Full text

Abstract:

A diffúz nagy B-sejtes limfóma 5 éves általános túlélése a mai kezelések mellett 60–70%, melynek hátterében a betegség komplex heterogenitása állhat.CélkitűzésMagyarországi multicentrikus tanulmányban a betegség fenotipikus, citogenetikai, genomexpressziós profil- és geográfiai heterogenitásának vizsgálata.MódszerA 276 formol-paraffinos betegmintát Hans' algoritmus és dupla protein expresszor státusz alapján klasszifikáltuk. A IGH::MYC, IGH::BCL2, BCL6 gén átrendeződéseket, valamint a MYC, BCL2 és BCL6 gének nyerését interfázis citogenetikával vizsgáltuk. Az RNA-seq-alapú génexpressziós profil

APA, Harvard, Vancouver, ISO, and other styles

44

Misyurina, A. E., S. K. Kravchenko, A. M. Kovrigina, et al. "The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data." Terapevticheskii arkhiv 91, no. 7 (2019): 52–62. http://dx.doi.org/10.26442/00403660.2019.07.000070.

Full text

Abstract:

Aim of the issue was to compare clinical characteristics and treatment results of patients with follicular lymphoma (FL) with translocations involving loci of c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes and patients with high - grade B-cell lymphoma [High - grade B-cell lymphoma (HGBL), double - hit (DH)]. Materials and methods. Since 2004 to 2017 years in National Research Center for Hematology 12 patients with high - grade B-cell lymphoma double - hit (HGBL DH) and 6 FL patients with translocations involving c-MYC and BCL2 and/or BCL6 had been treated. We performed a comparative analysis o

APA, Harvard, Vancouver, ISO, and other styles

45

Patel, Priyank P., Alison Zeccola, Vishala T. Neppalli, et al. "Pre-Clinical Investigation of Targeted Therapies for Double Hit Diffuse Large B-Cell Lymphoma (DH-DLBCL)." Blood 126, no. 23 (2015): 5122. http://dx.doi.org/10.1182/blood.v126.23.5122.5122.

Full text

Abstract:

Abstract Background: Molecular studies divide DLBCL into three subtypes with distinct pathogenesis and clinical outcomes: activated B-cell (ABC), germinal center B-cell (GCB) and primary mediastinal lymphoma (PML). Florescence in situ hybridization (FISH) studies identified another subgroup of DLBCL, classified as DH-DLBCL, with a poor clinical outcome harboring concurrent gene rearrangements of the c-MYC, BCL2 and/or BCL6 proto-oncogenes, resulting in the over-expression of c-Myc, Bcl2 and Bcl6 proteins. DH-DLBCL has inferior response rates (RR) to rituximab-based chemotherapy, and a shorter

APA, Harvard, Vancouver, ISO, and other styles

46

Khurana, Arushi, Raphael Mwangi, James R. Cerhan, et al. "Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications." Blood 142, Supplement 1 (2023): 67. http://dx.doi.org/10.1182/blood-2023-190316.

Full text

Abstract:

Background: High Grade B cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements(R) was introduced as an entity in 2016 by the WHO revised 4 th edition. In 2022, both the WHO 5 th edition (beta version) and the International Consensus Classification (ICC) separated DHL- BCL2 (+/- BCL6-R)from DHL- BCL6 given differences in biology . However, while the ICC has maintainedDHL- BCL6 as a provisional entity, the WHO has removed the category, thus removing the requirement to FISH for BCL6-R in this setting. Clinical data on DHL- BCL6 is much more limited, as these cases represent only 10-20

APA, Harvard, Vancouver, ISO, and other styles

47

Adam, Ammar, Kate Byth, Paul Secrist, et al. "A Dual Bcl-2/xL Inhibitor Induces Tumor Cell Apoptosis in a Hematopoietic Xenograft Model." Blood 124, no. 21 (2014): 5304. http://dx.doi.org/10.1182/blood.v124.21.5304.5304.

Full text

Abstract:

Abstract Over-expression of the antiapoptotic proteins Bcl-2 and Bcl-xL provides a common mechanism through which cancer cells gain a survival advantage and become resistant to conventional standard of care therapies. Because Bcl-2 family members play key, but partially overlapping, roles as regulators of apoptosis, simultaneous inhibition of both Bcl-2 and Bcl-xL could serve as a promising anticancer strategy. Clinical validation of this concept has been demonstrated with multiple agents targeting different Bcl2 family members. For example, recent Phase I/II trials of the dual Bcl-2 / Bcl-xL

APA, Harvard, Vancouver, ISO, and other styles

48

Saksena, Annapurna, Parth Desai, Zhuang Zuo, et al. "MYC/BCL2 Double Hit Lymphoma: What Really Matters." Blood 126, no. 23 (2015): 3909. http://dx.doi.org/10.1182/blood.v126.23.3909.3909.

Full text

Abstract:

Abstract Introduction: MYC/BCL2 double hit lymphoma (DHL), defined as a large B-cell lymphoma with concurrent MYC and BCL2 translocations, is the most common type of DHL. Although multiple studies focused on DHL have been published, several issues regarding impact on prognosis remain controversial including: 1) history of low grade B cell lymphoma; 2) morphology (diffuse large B-cell lymphoma [DLBCL] versus B cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma [BCLU)]; 3) Absence or low expression of MYC or BCL2; 4) MYC translocation partner gene; and esp

APA, Harvard, Vancouver, ISO, and other styles

49

Shen, Yige, Shu Cheng, Pengpeng Xu, Li Wang, and Weili Zhao. "Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma." Blood 142, Supplement 1 (2023): 4488. http://dx.doi.org/10.1182/blood-2023-188042.

Full text

Abstract:

Background: High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) is a recently defined category in the latest revision of the World Health Organization (WHO) classification, which comprises approximately 5-15% of newly diagnosed DLBCL. This subtype of lymphoma poses numerous challenges from diagnosis to treatment of patients. On the one hand, diagnosis of HGBL-DH/TH requires the accomplishment of fluorescent in-situ hybridization (FISH) to identify the translocations of MYC(8q24) and BCL2(18q21) or/and BCL6(3q27), with no consensus being reached regarding the mo

APA, Harvard, Vancouver, ISO, and other styles

50

Morschhauser, Franck, Yanwen Jiang, Fabrice Jardin, et al. "Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial." Journal of Clinical Oncology 40, no. 16_suppl (2022): 7517. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.7517.

Full text

Abstract:

7517 Background: Overexpression of BCL2 and MYC, and translocation of MYC, BCL2, and BCL6, are associated with poorer outcomes in patients (pts) with DLBCL (Horn et al. Blood 2013). We previously reported progression-free survival (PFS) from POLARIX in subgroups of pts with DLBCL receiving Pola-R-CHP or R-CHOP, including pts with double expressor lymphoma (DEL; favoring Pola-R-CHP: hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.42–0.97), and double- or triple-hit lymphoma (DHL/THL; favoring R-CHOP: HR 3.81, 95% CI 0.82–17.64) (Tilly et al. NEJM 2022). In this prespecified exploratory a

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!